中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 38 Issue 3
Mar.  2022
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2022  >  38(3): 703-707

Research advances in the features of nutrition metabolism and nutritional support in liver failure

DOI: 10.3969/j.issn.1001-5256.2022.03.043

  • Department of Infectious Diseases, Renmin Hospital of Wuhan University, Wuhan 430060, China

Research funding:

National Natural Science Foundation of China (82070609)

More Information
  • Corresponding author: GONG Zuojiong, zjgong@163.com(ORCID: 0000-0002-4676-5856)
  • Received Date: 2021-07-16
  • Accepted Date: 2021-08-16
  • Published Date: 2022-03-20
    Abstract
  • The liver is the main place for metabolism in human body, and when severe liver injury is induced by various factors, there will be disorders in the functions of synthesis, metabolism, and biological conversion. This article summarizes the features of the metabolism of nutrients such as glucose, amino acids, and lipids in the presence of liver failure, as well as the assessment of malnutrition and clinical interventions. For patients with liver failure, it is of great importance to identify and correct malnutrition in a timely manner, so as to improve energy metabolism and inflammation and increase survival rate.

     

    • FullText(HTML)
  • loading
    • References(50)
  • [1]
    SARIN SK, CHOUDHURY A, SHARMA MK, et al. Acute-on-chronic liver failure: Consensus recommendations of the Asian Pacific association for the study of the liver (APASL): An update[J]. Hepatol Int, 2019, 13(4): 353-390. DOI: 10.1007/s12072-019-09946-3.
    [2]
    Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association; Severe Liver Disease and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association. Guideline for diagnosis and treatment of liver failure(2018)[J]. J Clin Hepatol, 2019, 35(1): 38-44. DOI: 10.3969/j.issn.1001-5256.2019.01.007.

    中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南(2018年版)[J]. 临床肝胆病杂志, 2019, 35(1): 38-44. DOI: 10.3969/j.issn.1001-5256.2019.01.007.
    [3]
    ZHANG J, GAO S, DUAN Z, et al. Overview on acute-on-chronic liver failure[J]. Front Med, 2016, 10(1): 1-17. DOI: 10.1007/s11684-016-0439-x.
    [4]
    MENG QH, HOU W, YU HW, et al. Resting energy expenditure and substrate metabolism in patients with acute-on-chronic hepatitis B liver failure[J]. J Clin Gastroenterol, 2011, 45(5): 456-461. DOI: 10.1097/MCG.0b013e31820f7f02.
    [5]
    CHEN LY, YANG B, ZHOU L, et al. Promotion of mitochondrial energy metabolism during hepatocyte apoptosis in a rat model of acute liver failure[J]. Mol Med Rep, 2015, 12(4): 5035-5041. DOI: 10.3892/mmr.2015.4029.
    [6]
    LLIBRE-NIETO G, LIRA A, VERGARA M, et al. Micronutrient deficiencies in patients with decompensated liver cirrhosis[J]. Nutrients, 2021, 13(4): 1249. DOI: 10.3390/nu13041249.
    [7]
    PERUMPAIL BJ, LI AA, CHOLANKERIL G, et al. Optimizing the nutritional support of adult patients in the setting of cirrhosis[J]. Nutrients, 2017, 9(10): 1114. DOI: 10.3390/nu9101114.
    [8]
    YAO J, ZHOU X, WANG H, et al. Persistently increased resting energy expenditure predicts short-term mortality in patients with acute-on-chronic liver failure[J]. Ann Nutr Metab, 2018, 73(1): 2-9. DOI: 10.1159/000487604.
    [9]
    BERNARDI M, ANGELI P, CLARIA J, et al. Albumin in decompensated cirrhosis: New concepts and perspectives[J]. Gut, 2020, 69(6): 1127-1138. DOI: 10.1136/gutjnl-2019-318843.
    [10]
    ENGELMANN C, SHEIKH M, SHARMA S, et al. Toll-like receptor 4 is a therapeutic target for prevention and treatment of liver failure[J]. J Hepatol, 2020, 73(1): 102-112. DOI: 10.1016/j.jhep.2020.01.011.
    [11]
    FREIRE JORGE P, WIERINGA N, de FELICE E, et al. The association of early combined lactate and glucose levels with subsequent renal and liver dysfunction and hospital mortality in critically ill patients[J]. Crit Care, 2017, 21(1): 218. DOI: 10.1186/s13054-017-1785-z.
    [12]
    MOREAU R, CLÀRIA J, AGUILAR F, et al. Blood metabolomics uncovers inflammation-associated mitochondrial dysfunction as a potential mechanism underlying ACLF[J]. J Hepatol, 2020, 72(4): 688-701. DOI: 10.1016/j.jhep.2019.11.009.
    [13]
    DONG V, NANCHAL R, KARVELLAS CJ. Pathophysiology of acute liver failure[J]. Nutr Clin Pract, 2020, 35(1): 24-29. DOI: 10.1002/ncp.10459.
    [14]
    ZACCHERINI G, AGUILAR F, CARACENI P, et al. Assessing the role of amino acids in systemic inflammation and organ failure in patients with ACLF[J]. J Hepatol, 2021, 74(5): 1117-1131. DOI: 10.1016/j.jhep.2020.11.035.
    [15]
    NISHIKAWA T, BELLANCE N, DAMM A, et al. A switch in the source of ATP production and a loss in capacity to perform glycolysis are hallmarks of hepatocyte failure in advance liver disease[J]. J Hepatol, 2014, 60(6): 1203-1211. DOI: 10.1016/j.jhep.2014.02.014.
    [16]
    MANSOURI A, GATTOLLIAT CH, ASSELAH T. Mitochondrial dysfunction and signaling in chronic liver diseases[J]. Gastroenterology, 2018, 155(3): 629-647. DOI: 10.1053/j.gastro.2018.06.083.
    [17]
    FAITOT F, RUHLAND E, ONCIOIU C, et al. Metabolomic profiling highlights the metabolic bases of acute-on-chronic and post-hepatectomy liver failure[J]. HPB (Oxford), 2019, 21(10): 1354-1361. DOI: 10.1016/j.hpb.2019.02.008.
    [18]
    TREFTS E, GANNON M, WASSERMAN DH. The liver[J]. Curr Biol, 2017, 27(21): r1147-r1151. DOI: 10.1016/j.cub.2017.09.019.
    [19]
    MASSAFRA V, MILONA A, VOS HR, et al. Farnesoid X receptor activation promotes hepatic amino acid catabolism and ammonium clearance in mice[J]. Gastroenterology, 2017, 152(6): 1462-1476. DOI: 10.1053/j.gastro.2017.01.014.
    [20]
    KINNY-KÖSTER B, BARTELS M, BECKER S, et al. Plasma amino acid concentrations predict mortality in patients with end-stage liver disease[J]. PLoS One, 2016, 11(7): e0159205. DOI: 10.1371/journal.pone.0159205.
    [21]
    DEJONG CH, van de POLL MC, SOETERS PB, et al. Aromatic amino acid metabolism during liver failure[J]. J Nutr, 2007, 137(6 Suppl 1): 1579s-1585s; discussion 1597s-1598s. DOI: 10.1093/jn/137.6.1579S.
    [22]
    NATESAN V, MANI R, ARUMUGAM R. Clinical aspects of urea cycle dysfunction and altered brain energy metabolism on modulation of glutamate receptors and transporters in acute and chronic hyperammonemia[J]. Biomed Pharmacother, 2016, 81: 192-202. DOI: 10.1016/j.biopha.2016.04.010.
    [23]
    DRUML W, FISCHER M, PIDLICH J, et al. Fat elimination in chronic hepatic failure: Long-chain vs medium-chain triglycerides[J]. Am J Clin Nutr, 1995, 61(4): 812-817. DOI: 10.1093/ajcn/61.4.812.
    [24]
    CHEN EQ, WANG ML, ZHANG DM, et al. Plasma apolipoprotein A-V predicts long-term survival in chronic hepatitis B patients with acute-on-chronic liver failure[J]. Sci Rep, 2017, 7: 45576. DOI: 10.1038/srep45576.
    [25]
    LIAN J, LI X, WANG Y, et al. Metabolite variations between acute-on-chronic liver failure and chronic liver failure caused by hepatitis B virus based on ultra-performance liquid chromatography mass spectrometry[J]. Biomed Pharmacother, 2016, 84: 994-1000. DOI: 10.1016/j.biopha.2016.09.079.
    [26]
    SANTOS BC, CORREIA M, ANASTÁCIO LR. Energy expenditure and liver transplantation: What we know and where we are[J]. JPEN J Parenter Enteral Nutr, 2021, 45(3): 456-464. DOI: 10.1002/jpen.1985.
    [27]
    CLEMMESEN JO, HØY CE, JEPPESEN PB, et al. Plasma phospholipid fatty acid pattern in severe liver disease[J]. J Hepatol, 2000, 32(3): 481-487. DOI: 10.1016/s0168-8278(00)80400-6.
    [28]
    MANKA P, OLLIGES V, BECHMANN LP, et al. Low levels of blood lipids are associated with etiology and lethal outcome in acute liver failure[J]. PLoS One, 2014, 9(7): e102351. DOI: 10.1371/journal.pone.0102351.
    [29]
    SCHWARZKOPF KM, QUECK A, THOMAS D, et al. Omega-3 and -6 fatty acid plasma levels are not associated with liver cirrhosis-associated systemic inflammation[J]. PLoS One, 2019, 14(1): e0211537. DOI: 10.1371/journal.pone.0211537.
    [30]
    European Association for the Study of the Liver. EASL Clinical Practice Guidelines on nutrition in chronic liver disease[J]. J Hepatol, 2019, 70(1): 172-193. DOI: 10.1016/j.jhep.2018.06.024.
    [31]
    MARAS JS, MAIWALL R, HARSHA HC, et al. Dysregulated iron homeostasis is strongly associated with multiorgan failure and early mortality in acute-on-chronic liver failure[J]. Hepatology, 2015, 61(4): 1306-1320. DOI: 10.1002/hep.27636.
    [32]
    ZIEGLER TR. Parenteral nutrition in the critically ill patient[J]. N Engl J Med, 2009, 361(11): 1088-1097. DOI: 10.1056/NEJMct0806956.
    [33]
    KAPPUS MR. Acute hepatic failure and nutrition[J]. Nutr Clin Pract, 2020, 35(1): 30-35. DOI: 10.1002/ncp.10462.
    [34]
    PLAUTH M. Nutritional intervention in chronic liver failure[J]. Visc Med, 2019, 35(5): 292-298. DOI: 10.1159/000502125.
    [35]
    O'BRIEN A, WILLIAMS R. Nutrition in end-stage liver disease: Principles and practice[J]. Gastroenterology, 2008, 134(6): 1729-1740. DOI: 10.1053/j.gastro.2008.02.001.
    [36]
    KORETZ RL, AVENELL A, LIPMAN TO. Nutritional support for liver disease[J]. Cochrane Database Syst Rev, 2012, (5): CD008344. DOI: 10.1002/14651858.CD008344.pub2.
    [37]
    TSAI JJ, KUO HC, LEE KF, et al. Proteomic analysis of plasma from rats following total parenteral nutrition-induced liver injury[J]. Proteomics, 2015, 15(22): 3865-3874. DOI: 10.1002/pmic.201500128.
    [38]
    WALSH TS, WIGMORE SJ, HOPTON P, et al. Energy expenditure in acetaminophen-induced fulminant hepatic failure[J]. Crit Care Med, 2000, 28(3): 649-654. DOI: 10.1097/00003246-200003000-00008.
    [39]
    SOSA HENRÍQUEZ M, GÓMEZ DE TEJADA ROMERO MJ. Cholecalciferol or calcifediol in the management of vitamin D deficiency[J]. Nutrients, 2020, 12(6): 1617. DOI: 10.3390/nu12061617.
    [40]
    HOU W, LI J, LU J, et al. Effect of a carbohydrate-containing late-evening snack on energy metabolism and fasting substrate utilization in adults with acute-on-chronic liver failure due to Hepatitis B[J]. Eur J Clin Nutr, 2013, 67(12): 1251-1256. DOI: 10.1038/ejcn.2013.163.
    [41]
    BIGOT A, TCHAN MC, THOREAU B, et al. Liver involvement in urea cycle disorders: A review of the literature[J]. J Inherit Metab Dis, 2017, 40(6): 757-769. DOI: 10.1007/s10545-017-0088-5.
    [42]
    BLAAUW R, NEL DG, SCHLEICHER GK. Plasma glutamine levels in relation to intensive care unit patient outcome[J]. Nutrients, 2020, 12(2): 402. DOI: 10.3390/nu12020402.
    [43]
    CLÀRIA J, STAUBER RE, COENRAAD MJ, et al. Systemic inflammation in decompensated cirrhosis: Characterization and role in acute-on-chronic liver failure[J]. Hepatology, 2016, 64(4): 1249-1264. DOI: 10.1002/hep.28740.
    [44]
    WU W, SUN S, WANG Y, et al. Circulating neutrophil dysfunction in HBV-related acute-on-chronic liver failure[J]. Front Immunol, 2021, 12: 620365. DOI: 10.3389/fimmu.2021.620365.
    [45]
    ARROYO V, ANGELI P, MOREAU R, et al. The systemic inflammation hypothesis: Towards a new paradigm of acute decompensation and multiorgan failure in cirrhosis[J]. J Hepatol, 2021, 74(3): 670-685. DOI: 10.1016/j.jhep.2020.11.048.
    [46]
    FERNÁNDEZ J, CLÀRIA J, AMORÓS A, et al. Effects of albumin treatment on systemic and portal hemodynamics and systemic inflammation in patients with decompensated cirrhosis[J]. Gastroenterology, 2019, 157(1): 149-162. DOI: 10.1053/j.gastro.2019.03.021.
    [47]
    PRADELLI L, KLEK S, MAYER K, et al. Omega-3 fatty acid-containing parenteral nutrition in ICU patients: Systematic review with meta-analysis and cost-effectiveness analysis[J]. Crit Care, 2020, 24(1): 634. DOI: 10.1186/s13054-020-03356-w.
    [48]
    KULKARNI AV, ANAND L, VYAS AK, et al. Omega-3 fatty acid lipid emulsions are safe and effective in reducing endotoxemia and sepsis in acute-on-chronic liver failure: An open-label randomized controlled trial[J]. J Gastroenterol Hepatol, 2021, 36(7): 1953-1961. DOI: 10.1111/jgh.15400.
    [49]
    ZACHARIAS T, FERREIRA N, CARIN AJ. Preoperative immunonutrition in liver resection-a propensity score matched case-control analysis[J]. Eur J Clin Nutr, 2014, 68(8): 964-969. DOI: 10.1038/ejcn.2014.113.
    [50]
    LÓPEZ-VICARIO C, CHECA A, URDANGARIN A, et al. Targeted lipidomics reveals extensive changes in circulating lipid mediators in patients with acutely decompensated cirrhosis[J]. J Hepatol, 2020, 73(4): 817-828. DOI: 10.1016/j.jhep.2020.03.046.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (665) PDF downloads(81) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return